Abstract

Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF

Author(s): Geiger Christine M, Sorenson Bridget, Whaley Paul

Issue: Sep/Oct 2015 - Volume 19, Number 5

Page(s): 420-427

Download in electronic PDF format for $75
  • Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF Page 1
  • Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF Page 2
  • Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF Page 3
  • Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF Page 4
  • Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF Page 5
  • Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF Page 6
  • Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF Page 7
  • Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF Page 8

Abstract

The stability of 10 active pharmaceutical ingredients was studied in SyrSpend SF PH4 or SyrSpend SF Alka at room and/or refrigerated temperature (2°C to 8°C). An oral suspension of each active pharmaceutical ingredient was compounded in low actinic plastic bottles at a specific concentration in SyrSpend SF PH4 or SyrSpend SF Alka. Samples were assessed for stability immediately after preparation (day 0) followed by storage at room temperature and/or at refrigerated temperature. At set time points, the samples were removed from storage and assayed using a high-performance liquid chromatographic stability-indicating method. The active pharmaceutical ingredient was considered stable if the suspension retained 90% to 110% of the initial concentration. Furosemide was stable for at least 14 days in SyrSpend SF Alka at refrigerated conditions. Prednisolone sodium phosphate in SyrSpend SF PH4 was stable for at least 30 days at room temperature and refrigerated conditions. Ranitidine hydrochloride suspensions in SyrSpend SF PH4 at room temperature and refrigerated conditions were stable for at least 30 days and 58 days, respectively. Hydrocortisone hemisuccinate and sodium phosphate retained greater than 90% for at least 60 days at both room temperature and refrigerated samples in SyrSpend SF PH4. Amiodarone hydrochloride and nifedipine suspensions at both room temperature and refrigerated conditions retained greater than 90% of the initial concentrations for at least 90 days in SyrSpend SF PH4. Refrigerated samples of simvastatin in SyrSpend SF PH4 were stable for at least 90 days. Spironolactone in SyrSpend SF PH4 at room temperature retained more than 90% of the initial concentration for at least 90 days. Phenobarbital in SyrSpend SF PH4 retained above 90% of initial concentration for at least 154 days at room temperature. This study demonstrated the stability of a wide range of frequently used active pharmaceutical ingredients, tested in SyrSpend SF PH4 and SyrSpend SF Alka at different storage conditions.

Related Keywords

  • oral suspension vehicle
  • stability
  • SyrSpend SF
  • sugar free
  • storage temperature
  • amiodarone hydrochloride
  • furosemide
  • hydrocortisone hemisuccinate
  • hydrocortisone sodium phosphate
  • nifedipine
  • phenobarbital
  • prednisolone sodium phosphate
  • ranitidine hydrochloride
  • simvastatin
  • spironolactone

Related Categories

  • EXCIPIENTS
  • PEER-REVIEWED
  • STABILITIES, COMPATIBILITIES

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Sep/Oct 2015
Pg. 420-427
Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF
Author(s): Geiger Christine M, Sorenson Bridget, Whaley Paul
Jul/Aug 2020
Pg. 315
Hydrocortisone Hemisuccinate 2 mg/mL or Hydrocortisone Sodium Phosphate 2 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Jan/Feb 2018
Pg. 66-75
Stability of an Alcohol-free, Dye-free Hydrocortisone (2 mg/mL) Compounded Oral Suspension
Author(s): Manchanda Arushi, Laracy Melissa, Savji Taslim, Bogner Robin H
May/Jun 2011
Pg. 255-258
Stability of Verapamil Hydrochloride in SyrSpend SF Compared to Sorbitol Containing Syrup and Suspending Vehicles
Author(s): Voudrie Mark A, Alexander Bridget, Allen D Brett
Jul/Aug 2013
Pg. 344-346
Stability of Midazolam in SyrSpend SF and SyrSpend SF Cherry
Author(s): Geiger Christine M, Sorenson Bridget, Whaley Paul A
Sep/Oct 2003
Pg. 389-393
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Author(s): Alexander Kenneth S, Thyangarajapuram N
Jan/Feb 2010
Pg. 82-85
Stability of Oseltamivir Phosphate in SyrSpend SF, Cherry Syrup, and SyrSpend SF (For Reconstitution)
Author(s): Voudrie Mark A II, Allen D Brett
Sep/Oct 2021
Pg. 431-439
Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt
Author(s): Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A
Jul/Aug 2020
Pg. 327-336
Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Author(s): Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
May/Jun 2020
Pg. 252-262
Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4
Author(s): Polonini Hudson, Loures da Silva Sharlene, Neves Cunha Carolina, de Oliveira Ferreira Anderson, Anagnostou Korina, Dijkers Eli
Sep/Oct 2015
Pg. 428-431
Stability of Levothyroxine, Doxycycline, Hydrocortisone, and Pravastatin in Liquid Dosage Forms Stored at Two Temperatures
Author(s): Nahata Milap C
Jul/Aug 2012
Pg. 347-349
Stability of Gabapentin in SyrSpend SF
Author(s): Sorenson Bridget, Voudrie Mark A II, Gehrig Dan
Nov/Dec 2012
Pg. 513-515
Stability of Propranolol Hydrochloride in SyrSpend SF
Author(s): Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
Jan/Feb 2020
Pg. 54
Amiodarone Hydrochloride 5 mg/mL in SyrSpend SF pH4 Cherry Flavored
Author(s): Allen Loyd V Jr
Sep/Oct 2014
Pg. 427-431
Physicochemical and Microbiological Stabilities of Hydrocortisone in InOrpha Suspending Agent Studied Under Various Condition
Author(s): Bourget Philippe, Amin Alexandre, Vidal Fabrice, Pieyre Manon, Dosso El Ourmar, Beauvais Raphaelle, Loeuillet Richard
Mar/Apr 2020
Pg. 133
Minocycline Hydrochloride 10 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Jan/Feb 2010
Pg. 76-77
Chemical Stability of Hydrocortisone in Humco Simple Syrup and Ora-Sweet Vehicle
Author(s): Gupta Vishnu D
Sep/Oct 2010
Pg. 430-435
Quality Control and Physical and Chemical Stability of Hydrocortisone Oral Suspension: An Interlaboratory Study
Author(s): Santoveña A, Llabrés M, Fariña JB
Nov/Dec 2008
Pg. 558-564
Stability of Metronidazole Benzoate in SyrSpend SF One-Step Suspension System
Author(s): Vu Nicole T, Aloumanis Vasileios, Ben Michel J, Kupiec Thomas C, Patterson Evelyn K, Radke Joshua, Erickson Martin A III, Schneider Gary
Nov/Dec 2018
Pg. 516-526
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Author(s): Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira